Asia-Pacific Vaccines Market Expected to Reach $19.9 Billion by 2033

A vaccine is a biological substance designed to provide immunity against a specific infectious disease. It contains weakened, inactivated, or parts of a pathogen, which stimulate the body's immune system to recognize and combat the disease without causing the illness itself. By producing antibodies and memory cells, vaccines prepare the immune system for future encounters with the actual pathogen, significantly reducing the risk of infection or lessening its severity. Vaccination is a crucial tool in preventing widespread infectious diseases.

Asia-Pacific vaccines market growth is primarily driven increase in awareness about the importance of immunization, coupled with rise in government initiatives to expand vaccination programs. Governments in the region are actively investing in healthcare infrastructure, implementing national immunization programs, and partnering with international organizations to improve vaccine coverage, particularly in rural and underserved areas. The prevalence of infectious diseases such as influenza, measles, and hepatitis has heightened the focus on widespread vaccination, contributing significantly to the growth during Asia-Pacific vaccines market forecast period. In addition, international collaborations to promote vaccine equity and address immunization gaps also drives the Asia-Pacific vaccines market growth.

However, high costs of certain vaccines, particularly for low-income populations, and inadequate funding for immunization programs further restrict the market growth. In addition, regulatory hurdles and lengthy approval processes in some countries can delay vaccine introduction and hinder the market growth. However, Asia-Pacific vaccines market trends includes government focus on immunization programs and public-private partnerships aimed at expanding vaccine access which provide opportunities for the Asia-Pacific vaccines industry growth. The region's large, diverse population provides a significant target base for both existing and novel vaccines, particularly given the ongoing prevalence of infectious diseases.

Industry Trends

• In 2023, World Health Organization (WHO) and United Nations International Children's Emergency Fund (UNICEF) reported a concerning stall in global childhood immunization rates, with increase in unvaccinated children as compared to pre-pandemic levels. This trend is particularly pronounced in conflict-affected regions of Asia-Pacific, where access to healthcare remains severely disrupted. The number of children who did not receive a single dose of the vaccine increased from 13.9 million in 2022 to 14.5 million in 2023. The report emphasizes the urgent need for investments in primary healthcare systems to close immunization gaps. As countries prioritize improving healthcare infrastructure and vaccination outreach, which is expected to be a corresponding rise in demand for vaccines. 

Segment Highlights

The vaccines market size is segmented on the basis of technology type, indication, end user, and country. On the basis of the technology type,  the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. The recombinant and conjugate vaccines segment accounted for the largest Asia-Pacific vaccines market share in 2023. This is attributed to their effectiveness in targeting a wide range of infectious diseases. These vaccines elicit strong immune responses and provide long-lasting protection, making them vital for public health initiatives. In addition, advancements in vaccine technology have enhanced the production and availability of these vaccines across the region.

On the basis of indication, the Asia-Pacific vaccines market size is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP) , polio, hepatitis, and other indications. The pneumococcal disease segment accounted for the largest Asia-Pacific vaccines market share in 2023. This is attributed to rise in prevalence of pneumococcal infections and their associated morbidity and mortality rates. On the basis of end user, the market segmented into pediatric, adults, and travelers.Country-wise the market is classified into Japan, China, India,  Australia,  South Korea, and Rest of Asia-Pacific.

Chongqing Zhifei Biological Products Co., Ltd, Bharat Biotech, DAIICHI SANKYO COMPANY, LIMITED, Merck & Co., Inc., Sanofi, AstraZeneca, Pfizer, CSL, Serum Institute of India Pvt. Ltd., and Vaxine Pty Ltd.  are the key players operating in the Asia-Pacific vaccines industry. These key players adopt strategies such as product approval, agreement and others to expand the portfolio. For instance, in June 2024, Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its PROVARIX (Varicella Vaccine (Vero Cell) , Live) has been approved by the China National Medical Products Administration (NMPA) for the use in adolescents and adults aged 13 and above on June 14, 2024.